Welcome to our newsroom. Here you will find images and press releases.
Secured funding for Moroxite F
Moroxite F has carried out a new share issue to existing owners of the company securing just over 10 MSEK of which 5 MSEK has been received by the company and 5 MSEK will be paid in April 2024.
The capital ensures a continued high rate of development in the company, which has several ongoing and planned studies and is working intensively on product development.
‘It is reassuring and gratifying for all of us at Moroxite F to have secured the funds to be able to continue working with strong progress’ comments Semmy Rülf, Chairman of the Board.
Ethical approval granted for a randomized controlled trial in trochanteric fractures using Moroxite F’s FARE procedure
Assistant Professor Erdem Aras Sezgin at Aksaray University of Medicine, Department of Orthopedics and Traumatology, Turkey has on September 14, 2023 received ethical approval for a RCT in trochanteric fractures operated with a Gamma nail using the FARE procedure. The study will be monitored by an external CRO.
This is the second clinical RCT with the aim to improve implant fixation in unstable trochanteric fractures and prevent reoperations. It follows several preclinic studies in osteoporotic animals published by the inventors of the FARE concept.
Introducing New Members to Team Moroxite F
We are delighted to introduce two talented professionals who have recently joined our team:
- Anna Szilagyi comes on board as the Director of Design and Development, bringing with her a wealth of expertise in Research and Development in the medical device and pharmaceutical industry.
- Linda Andersson joins us as the Director of Manufacturing and Supply. She brings with her a career spanning over 18 years, encompassing experience in R&D, Production, and Product Development.
Their collective experience and skill sets will help pave the way for an exciting new phase of growth and innovation.
Moroxite F team wraps up study in spine segment – Results Coming Soon!
Moroxite F team comprising of CTO Deepak Raina and doctoral student Jintian Huang accompanied by Prof. Stefan Zwingenberger and his team from Dresden as well as the highly profession team of veterinarians from the Lithuanian University of Health Sciences finished operating all mini-pigs in the spine project. We are now awaiting results which will be available in December 2023.
Exciting research collaboration to test bio-modulation for enhanced implant anchorage
Our research group has collaborated with Prof. Ding to test the Fracture Anchorage and Regeneration concept in a pre-clinical setting using their well-established model of implant integration. This study will experimentally verify the concept of bio-modulation for enhanced implant anchorage.
Our team Johan Tinnerholm, Kirsten Therkildsen Søndersted-Olsen, and Deepak Raina were thrilled to spend time with Prof. Ding and his group at the University of Southern Denmark, Odense last week
34orna 2022: Moroxite F CTO Deepak Raina named ‘34under34’ a future star in Skåne’s business community
On November 21st, PwC and Rapidus will present new and future stars in Skåne’s business community receiving the honourable award called 34:orna.
Moroxite F´s Chief Technical Officer, Deepak Raina, age 33, has been nominated and recognized as a PhD engineer and Scanian innovator with Indian background who together with a distinguished team of professors and business profiles in the region has founded Moroxite F. A company based on years of research aimed at developing the next generation therapeutics in osteoporosis.
The whole team at Moroxite F want to congratulate Deepak on this well-deserved recognition and testament to his work.
Moroxite F announces the appointment of Johan Tinnerholm as CEO
October 2022: We are pleased to announce the appointment of Johan Tinnerholm as the CEO of Moroxite F AB. Johan has a broad experience from leading roles at stock listed companies like Agilit Holding AB, Curando Nordic and Safeture. Building on what we have already accomplished, under Johan’s leadership we look forward to hone our strategic direction, grow and develop our organization, strengthen our investor relations, and build new partnerships.
Johan Tinnerholm, CEO Moroxite F
’Moroxite F is a very exciting company built on groundbreaking research. It is bound to make a big difference for those suffering from osteoporosis and related fractures. I look forward to working with the dedicated team to realize Moroxite F’s full potential.’
Invited talk by TERM group at LU at the Nordic Orthopedic Foundation's annual meeting
Researchers from TERM group at LU gave an invited talk on ‘A New Augmentation Method for Improved Screw Fixation in Fragile Bone With focus on trochanteric fractures’ at the Nordic Orthopedic Foundation’s annual meeting in Vilnius, Lithuania.
EORS and International combined orthopedic research society joint meeting
TERM group at LU presented their work a the recently held EORS and International Combined Orthopedic Research Society joint meeting.
First proof-of-concept study published in Frontiers in Bioengineering and Biotechnology
The term group at LU has published the first proof-of-concept study describing Moroxite F AB groundbreaking implant fixation technology in the journal Frontiers in Bioengineering and Biotechnology.
This peer-reviewed study demonstrates an enhanced immediate mechanical anchorage of a hip fracture fixation device to low quality osteoporotic bone both in laboratory studies as well as in a small set of patients.
Moroxite F’s tech package comprises of a method and a device for delivering hydroxyapatite particles at the interface of bone and a fracture fixation device without the use of additional pressure or complex surgical procedures, minimizing the risk of vascular leakage or complications for the patient.
Once the fixation device is placed at its final position, the HA particles reinforce the bone-implant interface and ensure an improved grip. For the sake of easing the imagination, the developed method can be considered analogous to placing a nail in a bad quality concrete wall (osteoporotic bone) vs. placing the screw in the same wall reinforced with additional cement.
The paper further validates the developed methodology in 5 patients undergoing treatment for a hip fracture and the results demonstrate excellent spreading of the HA material at the screw threads without obvious complications.
The final part of Moroxite F’s technology comprises of biologically activating the HA particles. This is performed by sending an anti-osteoporosis drug to the HA particles post-surgery via the blood stream. Our research group, TERM at Lund University’s pre- clinical research has shown that the administered clinical research has shown that the administered osteoporosis drug seeks the HA particles and imparts a pro-bone formation effect leading to new bone formation around the implant. This concept is now being verified in a clinical study, interim results of which will be presented at the Nordic Orthopedic Federations annual meeting in Vilnius, Lithuania in April 2022. The clinical study is expected to finish in June 2023.
A New Augmentation Method for Improved Screw Fixation in Fragile Bone. https://doi.org/10.3389/fbioe.2022.816250